Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-03-06
2007-03-06
Yaen, Christopher H. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S007240, C435S007800
Reexamination Certificate
active
09625137
ABSTRACT:
The present invention relates to the use of alpha (2) macroglobulin (“α2M”) receptor as a heat shock protein receptor, cells that express the α2M receptor bound to an HSP, and antibodies and other molecules that bind the α2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that modulate the interaction of an HSP with the α2M receptor, and methods for using compositions comprising α2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.
REFERENCES:
patent: 5112298 (1992-05-01), Prince et al.
patent: 5554293 (1996-09-01), Uhoch
patent: 5637082 (1997-06-01), Pages et al.
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5846928 (1998-12-01), Kishida
patent: 5935576 (1999-08-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5968526 (1999-10-01), Garman et al.
patent: 5985270 (1999-11-01), Srivastava
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6017540 (2000-01-01), Srivastava
patent: 6027731 (2000-02-01), Pauza
patent: 6033561 (2000-03-01), Schoendorfer
patent: 6156311 (2000-12-01), Strickland et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 2002/0001841 (2002-01-01), Kaltoft et al.
patent: WO 94/14471 (1994-07-01), None
patent: WO 94/14976 (1994-07-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/04794 (1997-02-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 98/46739 (1997-07-01), None
patent: WO 98/42752 (1998-10-01), None
patent: WO 98/46743 (1998-10-01), None
patent: WO 99/50303 (1999-10-01), None
patent: WO 00/03003 (2000-01-01), None
patent: WO 00/34494 (2000-06-01), None
patent: WO 00/38760 (2000-07-01), None
patent: WO 00/46246 (2000-08-01), None
patent: WO 00/54801 (2000-09-01), None
patent: WO 02/07755 (2002-01-01), None
Agostoni et al., 1994, “Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator.” Circulation. 90(6):2666-70.
Bednar et al., 1997, “Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke.” J. Neurosurg. 86(1):139-42.
Collen et al., 1989, “Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.” Drugs. 38(3):346-88.
Hanover et al., 1986, “Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake”, J. of Biol. Chem, 261(35): 16732-16737.
Herz et al., 1990, “Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver”, J. of Biol. Chem. 265(34): 21355-21362.
Herz et al., 1991, “39-kDa protein modulates binding of ligands to low density lipoprotein recpetor-related protein/alpha-2-macroglobulin receptor.” J.Biol.Chem. 266(31):21232-21238.
Hey et al., 1988, “Cloning of a novel member of the low-density lipoprotein receptor family”, Gene 216: 103-111.
Horn et al., 1995, “Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein recepetor-related protein using a Fab fragment selected from a phage-displayed Fab library”, J. of Biol. Chem. 270 (20): 11770-11775.
Huang et al., 1996, “The immunodominant major histocompatability complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product”, Proc. Natl. Acad. Sci. USA. 93:9730-9735.
Hughes et al., 1981, “Characterization of plasma membrane proteins identified by monoclonal antibodies”, J. of Biol./Chem. 256(2): 664-671.
Isaacs et al., 1988, “Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site”, J. Biol. Chem. 263(14): 6709-6714.
Katsutani et al., 1992, “Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice.” Fundam Appl Toxicol. 19(4):555-62.
Kim et al., 1998, “A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E”, J. Biochem. 124: 1072-1076.
Kimber et al., 2002, “Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation.” Biochem Cell Biol. 2002;80(1):103-7.
Moestrup et al., 1990, “Immunocytochemical identification of the human aplpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen”, Exper. Cell Res. 190: 195-203.
Moestrup et al., 1991, Analysis of Ligand Recognition by the purified alpha-2M-macroglobulin receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
Opekun et al., 1999, “Novel therapies forHeliobacter pyloriinfection.” Aliment Pharmacol Ther, 13(1):35-42.
Reed et al., 1990, “Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients.” Thromb Haemost. 64(2):276-80.
Warshawaky et al., 1993, “Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein,” J. Biol. Chem. 268(29):22046-22054.
Yamauchi et al., 2000, “Oral administration of bovine lactoferrin for treatment oftinea pedis. A placebo-controlled, double-blind study.” Mycoses.43(5):197-202.
Zimecki et al., 1999, “Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNT-alpha and IL-6 by peripheral blood cells.” Arch Immunol Ther Exp (Warsz). 47(2):113-8.
Zimecki et al., 1998, “Immnunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals.” Arch Immunol Ther Exp (Warsz). 46(4):231-40.
U.S. Appl. No. 09/411,075, P. Srivastava.
U.S. Appl. No. 60/209,095, P. Srivastava.
Arnold et al., 1995, , “Cross-priming of minor histocompaibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96”, J Exp Med. 182(3):885-9.
Arnold-Schild et al., 1999, “Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells”, J. Immunol. 1999, 162: 3757-3760.
Asea et al., 2000, “HSP70 stimulates cytokine production through a CD14 dependent pathway, demostrating its dual role as a chaperone and cytokine”, Nature Med. 6: 435-42.
Bevan, 1995, “Antigen presentation to cytotoxic T lymphocytes in vivo”, J.Exp. Med. 192: 639-41.
Binder et al., 1998, Cell Stress & Chaperones 3 (Supp.1): 2.
Castellino et al., 2000, “Receptor-mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways”, J. Exp. Med. 191: 1957-64.
Chen et al., 1999, “Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System”, J. Immunology 162: 3212-3219.
Chu and Pizzo, 1993, “Receptor mediated antigen delivery into macrophages. Complexing antigen to α2-macroglobulin enhances presentation into T cells”, J. Immun. 150(1):48-58.
Chu et al., 1994, “Adjuvant-Free in Vivo Targeting. Antigen Delivery by a α2-macroglobulin enhances antibody formation”, J. Immun. 152(4):1538-45.
Ciupitu et al., 1998, “Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes”, J Exp Med. 187(5):685-9
Binder Robert J.
Srivastava Pramod K.
Jones Day
University of Connecticut Health Center
Yaen Christopher H.
LandOfFree
Alpha(2) macroglobulin receptor as a heat shock protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha(2) macroglobulin receptor as a heat shock protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha(2) macroglobulin receptor as a heat shock protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3795639